States Target Mylan (MYL) Exec Malik in Generic Drug-Collusion Probe - Bloomberg
Get Alerts MYL Hot Sheet
Join SI Premium – FREE
(Updated - October 31, 2017 11:04 AM EDT)
Dozens of states are targeting Mylan (NASDAQ: MYL) president and executive director Rajiv Malik in a generic drug-collusion probe, Bloomberg reported.
State AGs are seeking to sue Rajiv Malik as part of an expanded complaint against pharmaceutical companies, according to a statement by Connecticut Attorney General George Jepsen.
Malik would be the first senior executive from a major drugmaker sued in the case.
"These conspiracies were part of a much broader, overarching industry code of conduct that enabled the defendant manufacturers to divvy up the market for specific generic drugs in accordance with an established, agreed-upon understanding for assigning each competitor their share of the market," Jepsen said in the statement.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- lululemon athletica (LULU) to close one of smaller distribution centers located in Sumner, WA at the end of 2024 - Reuters
- Super Micro Computer (SMCI) now down nearly 20%
- JPMorgan (JPM) Dealmakers Lipsky and Lee Leaving the Bank - Reuters
Create E-mail Alert Related Categories
FDA, Litigation, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!